We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...

Initial results found that among 1060 participants in 30 countries, the pembrolizumab plus CCRT group conferred better PFS at 24 months than the placebo plus CCRT group (68% vs 57%; hazard ratio [HR], ...

After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...